Literature DB >> 23054468

Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.

Ymir Saemundsson1, Signý Vala Sveinsdottir, Henrik Svantesson, Peter J Svensson.   

Abstract

The most common forms of familial thrombophilia are factor V Leiden (FVL) and prothrombin mutation (PTM). Homozygous FVL and PTM have long been feared conditions thought to cause high rates of morbidity and mortality. To analyse clinical features in patients with homozygous FVL and PTM, as well as patients with double heterozygosity for FVL and PTM. All patients with homozygous FVL, PTM or double heterozygosity in the MATS database of 1465 consecutive unselected patients were analysed regarding age at inclusion venous thromboembolism (VTE), age at first thrombosis, recurrence, clinical course and acquired risk factors. We found 36 patients homozygous for FVL. Patients homozygous for FVL were younger than controls at group level (56 ± 18 vs. 63 ± 17, p < 0.02). Homozygous women were younger than female controls (50 ± 19 vs. 63 ± 18, p < 0.002). No difference was observed when comparing male subjects. Women were younger than men at inclusion thrombosis (50 ± 19 vs. 65 ± 14, p < 0.02) and at first thrombosis (47 ± 19 vs. 64 ± 14, p < 0.01). Deep venous thrombosis (DVT) was seen in 33 patients (92 %), 6 (17 %) had pulmonary embolism (PE) and 3 (8 %) had combined DVT and PE. PE was less frequent in homozygous FVL women compared to female controls (p < 0.03). VTE recurred in 3 subjects during the duration of the study. Odds ratio for VTE in homozygous FVL patients compared to controls was 13.9 (95 % CI 9.9-19.7). We found no subjects with homozygous PTM. Double heterozygosity for FVL and PTM was seen in 12 subjects. There was no difference in age at inclusion VTE between double heterozygotes and controls (59 ± 16 vs. 63 ± 17, ns.). DVT was seen in 92 % at inclusion, 8 % had PE. Mean age at first VTE was 52 ± 17 (27-82). Consecutive homozygous FVL patients had a higher age at first thrombosis than previously described. Homozygous females are affected at an earlier age than homozygous men and female controls. It seems that thrombi in homozygous FVL have a different pattern compared to controls i.e. more prone for thrombosis in the lower extremity. The odds ratio for thrombosis among homozygous FVL seems to be lower than previously described.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23054468     DOI: 10.1007/s11239-012-0824-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  26 in total

1.  Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.

Authors:  Willem M Lijfering; Saskia Middeldorp; Nic J G M Veeger; Karly Hamulyák; Martin H Prins; Harry R Büller; Jan van der Meer
Journal:  Circulation       Date:  2010-04-05       Impact factor: 29.690

Review 2.  Advances in understanding pathogenic mechanisms of thrombophilic disorders.

Authors:  Björn Dahlbäck
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

3.  Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation.

Authors:  O Björgell; P E Nilsson; J A Nilsson; P J Svensson
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

4.  Factor V Leiden mutation and pregnancy-related complications.

Authors:  Ulla Kjellberg; Marianne van Rooijen; Katarina Bremme; Margareta Hellgren
Journal:  Am J Obstet Gynecol       Date:  2010-11       Impact factor: 8.661

5.  Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.

Authors:  I Martinelli; M Cattaneo; D Panzeri; P M Mannucci
Journal:  Thromb Haemost       Date:  1997-03       Impact factor: 5.249

6.  A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.

Authors:  Aaron R Folsom; Mary Cushman; Michael Y Tsai; Nena Aleksic; Susan R Heckbert; Lori L Boland; Albert W Tsai; N David Yanez; Wayne D Rosamond
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

7.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

Authors:  Paolo Prandoni; Franco Noventa; Angelo Ghirarduzzi; Vittorio Pengo; Enrico Bernardi; Raffaele Pesavento; Matteo Iotti; Daniela Tormene; Paolo Simioni; Antonio Pagnan
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

8.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

9.  Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS).

Authors:  Nazim Isma; Peter J Svensson; Anders Gottsäter; Bengt Lindblad
Journal:  Thromb Res       Date:  2009-06-03       Impact factor: 3.944

10.  Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.

Authors:  C Rintelen; C Mannhalter; H Ireland; D A Lane; P Knöbl; K Lechner; I Pabinger
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

View more
  5 in total

1.  Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism.

Authors:  Ashfaque A Memon; Kristina Sundquist; Xiao Wang; Peter J Svensson; Jan Sundquist; Bengt Zöller
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

2.  Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.

Authors:  Gianluca Gessoni; Sara Valverde; Letizia Valle; Pierpaolo Caruso; Francesca Gessoni; Roberto Valle
Journal:  Blood Transfus       Date:  2017-03-07       Impact factor: 3.443

3.  Potential Risk Factors Associated With Vascular Diseases in Patients Receiving Treatment for Hypertension.

Authors:  Hyunjung Kim; Joonhong Park; Hyojin Chae; Gun Dong Lee; Sang Yoon Lee; Jong Min Lee; Yong Seog Oh; Myungshin Kim; Yonggoo Kim
Journal:  Ann Lab Med       Date:  2016-05       Impact factor: 3.464

4.  Thrombophilia testing: A British Society for Haematology guideline.

Authors:  Deepa J Arachchillage; Lucy Mackillop; Arvind Chandratheva; Jayashree Motawani; Peter MacCallum; Mike Laffan
Journal:  Br J Haematol       Date:  2022-05-29       Impact factor: 8.615

5.  Fingertips ischemia, nephroangiosclerosis, and focal segmental glomerulosclerosis: is genetic thrombophilia the unique explanation?

Authors:  Lisa Giovannini; Carlo Donadio
Journal:  Case Rep Med       Date:  2014-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.